Google-owner Alphabet helped drive the Nasdaq to an all-time high on Tuesday despite investor uncertainty surrounding the ...

The stock market fell today as investors braced for a major tax raid in tomorrow’s Budget. The benchmark FTSE 100 dropped ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

NEW YORK, Oct 15 (Reuters) - Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock has dropped over 50% since its pandemic peak, following a series of ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on the action. Pfizer is laying out $49 million upfront in a partnership ...